NEKTAR THERAPEUTICS — Director's Dealing 2016

Aug 17, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2016-08-16

Reporting Person: Gergel Ivan P. (SVP & Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-08-16	Common Stock	S	1685	$17.56	Disposed	27327	Direct

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $17.47 to $17.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F2: The total holdings include the remaining portion of the 15,000 shares of restricted stock units ("RSUs") that were previously reported in Table II for the reporting person and which are being reclassified to Table I. These RSUs were granted on December 15, 2015, are convertible on a one-for-one basis into shares of Common Stock of the Company, and vest on a quarterly pro-rata basis over a period of three (3) years from the date of grant.